Magdolna Herold

482 total citations
37 papers, 387 citations indexed

About

Magdolna Herold is a scholar working on Oncology, Cancer Research and Surgery. According to data from OpenAlex, Magdolna Herold has authored 37 papers receiving a total of 387 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 9 papers in Cancer Research and 8 papers in Surgery. Recurrent topics in Magdolna Herold's work include Inflammatory Biomarkers in Disease Prognosis (8 papers), Cancer, Lipids, and Metabolism (7 papers) and Pancreatic and Hepatic Oncology Research (6 papers). Magdolna Herold is often cited by papers focused on Inflammatory Biomarkers in Disease Prognosis (8 papers), Cancer, Lipids, and Metabolism (7 papers) and Pancreatic and Hepatic Oncology Research (6 papers). Magdolna Herold collaborates with scholars based in Hungary, Austria and Germany. Magdolna Herold's co-authors include Anikó Somogyi, Zoltán Herold, RA Bowden, Guenther Gastl, C. Huber, Walter E. Aulitzky, Bernhard Meister, W. Woloszczuk, Magdolna Dank and Nóra Adányi and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Scientific Reports.

In The Last Decade

Magdolna Herold

34 papers receiving 380 citations

Peers

Magdolna Herold
Sara Oppi Italy
Fiona R. Green United Kingdom
Maha Ahmed Egypt
James R. Smith United Kingdom
D. M. Humphrey United States
Lucía Tejedor-Santamaria Spain
Dijiong Wu China
Mee Jeong Lee South Korea
Jamie Robertson United Kingdom
Chengyu Liu United States
Sara Oppi Italy
Magdolna Herold
Citations per year, relative to Magdolna Herold Magdolna Herold (= 1×) peers Sara Oppi

Countries citing papers authored by Magdolna Herold

Since Specialization
Citations

This map shows the geographic impact of Magdolna Herold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Magdolna Herold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Magdolna Herold more than expected).

Fields of papers citing papers by Magdolna Herold

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Magdolna Herold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Magdolna Herold. The network helps show where Magdolna Herold may publish in the future.

Co-authorship network of co-authors of Magdolna Herold

This figure shows the co-authorship network connecting the top 25 collaborators of Magdolna Herold. A scholar is included among the top collaborators of Magdolna Herold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Magdolna Herold. Magdolna Herold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Garay, Tamás, Magdolna Herold, Alexandra Simon, et al.. (2024). Immune Marker and C-Reactive Protein Dynamics and Their Prognostic Implications in Modulated Electro-Hyperthermia Treatment in Advanced Pancreatic Cancer: A Retrospective Analysis. SHILAP Revista de lepidopterología. 4(4). 385–399. 1 indexed citations
2.
3.
Szász, Attila Marcell, Giammaria Fiorentini, Magdolna Herold, et al.. (2023). Meta-Analysis of Modulated Electro-Hyperthermia and Tumor Treating Fields in the Treatment of Glioblastomas. Cancers. 15(3). 880–880. 5 indexed citations
4.
Dank, Magdolna, Magdolna Herold, Zoltán Herold, et al.. (2023). Prolonged hyperthermic intraperitoneal chemotherapy duration with 90 minutes cisplatin might increase overall survival in gastric cancer patients with peritoneal metastases. World Journal of Gastroenterology. 29(18). 2850–2863. 2 indexed citations
5.
Herold, Zoltán, Tamás Garay, Magdolna Herold, et al.. (2023). High Tumor-Infiltrating Lymphocyte Count Is Associated with Distinct Gene Expression Profile and Longer Patient Survival in Advanced Ovarian Cancer. International Journal of Molecular Sciences. 24(18). 13684–13684. 3 indexed citations
6.
Herold, Magdolna, Attila Marcell Szász, Gyöngyvér Szentmártoni, et al.. (2023). Influence of the duration of type 2 diabetes mellitus on colorectal cancer outcomes. Scientific Reports. 13(1). 12985–12985. 3 indexed citations
7.
Somogyi, Anikó, Magdolna Herold, Klára Rosta, et al.. (2022). Does diabetes affect paraneoplastic thrombocytosis in colorectal cancer?. Open Medicine. 17(1). 160–173. 3 indexed citations
8.
Herold, Zoltán, et al.. (2022). Longitudinal changes in personalized platelet count metrics are good indicators of initial 3-year outcome in colorectal cancer. World Journal of Clinical Cases. 10(20). 6825–6844. 6 indexed citations
9.
Herold, Zoltán, et al.. (2022). High plasma CD40 ligand level is associated with more advanced stages and worse prognosis in colorectal cancer. World Journal of Clinical Cases. 10(13). 4084–4096. 8 indexed citations
10.
Nagy, Géza, et al.. (2022). New therapeutic approaches for type 1 diabetes: Disease-modifying therapies. World Journal of Diabetes. 13(10). 835–850. 12 indexed citations
11.
Dank, Magdolna, et al.. (2022). Does Elevated Pre-Treatment Plasma PD-L1 Level Indicate an Increased Tumor Burden and Worse Prognosis in Metastatic Colorectal Cancer?. Journal of Clinical Medicine. 11(16). 4815–4815. 4 indexed citations
12.
Molnár, Zsuzsanna, Zsófia Bánlaki, Anikó Somogyi, et al.. (2020). Diabetes-specific Modulation of Peripheral Blood Gene Expression Signatures in Colorectal Cancer. Current Molecular Medicine. 20(10). 773–780. 6 indexed citations
13.
Herold, Zoltán, Magdolna Herold, Péter Nagy, et al.. (2020). Regular chromogranin A monitoring facilitated the early detection of a gastrointestinal neuroendocrine tumour in a patient with type 1 diabetes. Endokrynologia Polska. 71(5). 483–484. 1 indexed citations
14.
Herold, Zoltán, Magdolna Herold, Klára Rosta, Márton Doleschall, & Anikó Somogyi. (2020). Lower serum chromogranin B level is associated with type 1 diabetes and with type 2 diabetes patients with intensive conservative insulin treatment. Diabetology & Metabolic Syndrome. 12(1). 61–61. 6 indexed citations
15.
Herold, Zoltán, Magdolna Herold, Péter Nagy, et al.. (2019). Serum chromogranin A level continuously rises with the progression of type 1 diabetes, and indicates the presence of both enterochromaffin‐like cell hyperplasia and autoimmune gastritis. Journal of Diabetes Investigation. 11(4). 865–873. 12 indexed citations
16.
Farkas, Katalin, et al.. (2004). Impairment of the NO/cGMP Pathway in the Fasting and Postprandial State in Type 1 Diabetes Mellitus. Experimental and Clinical Endocrinology & Diabetes. 112(5). 258–263. 18 indexed citations
17.
Ebenbichler, Christoph, Susanne Kaser, Johannes Bodner, et al.. (2001). Hyperhomocysteinemia in bodybuilders taking anabolic steroids. European Journal of Internal Medicine. 12(1). 43–47. 21 indexed citations
18.
Zeimet, Alain G., Martin Widschwendter, Cornelius Knabbe, et al.. (1998). Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer.. Journal of Clinical Oncology. 16(5). 1861–1868. 68 indexed citations
19.
Herold, Magdolna, W. Woloszczuk, Walter E. Aulitzky, et al.. (1990). ENDOGENOUS IFN-GAMMA DURING HUMAN BONE MARROW TRANSPLANTATION. Transplantation. 50(4). 620–624. 98 indexed citations
20.
Marth, Christian, Günther Gastl, Magdolna Herold, et al.. (1989). Die intraperitoneale Instillation von Interferon-gamma zur Behandlung des refraktären Ovarialkarzinoms. Geburtshilfe und Frauenheilkunde. 49(11). 987–991. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sara Oppi Breakdown of academic impact, for papers by Fiona R. Green Breakdown of academic impact, for papers by Maha Ahmed Breakdown of academic impact, for papers by James R. Smith Breakdown of academic impact, for papers by D. M. Humphrey Breakdown of academic impact, for papers by Lucía Tejedor-Santamaria Breakdown of academic impact, for papers by Dijiong Wu Breakdown of academic impact, for papers by Mee Jeong Lee Breakdown of academic impact, for papers by Jamie Robertson Breakdown of academic impact, for papers by Chengyu Liu
Rankless by CCL
2026